Clinical Trials
74 trialsNCT02193282 2026-05-04
Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02296125 2026-04-21
FLAURA
AstraZeneca
Phase 3 Completed
NCT01013649 2026-02-23
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT02152631 2026-02-06
JUNIPER
Eli Lilly and Company
Phase 3 Active not recruiting
NCT02411448 2026-01-16
RELAY
Eli Lilly and Company
Phase 3 Active not recruiting
NCT00446225 2025-03-05
EURTAC
Spanish Lung Cancer Group
Phase 3 Completed
NCT02588261 2024-12-10
SOLAR
Astellas Pharma Inc
Phase 3 Terminated
NCT02352948 2024-07-26
ARCTIC
AstraZeneca
Phase 3 Completed
NCT02633189 2023-03-24
BEVERLY
National Cancer Institute, Naples
Phase 3 Unknown
NCT01652469 2022-08-24
EMPHASIS
ETOP IBCSG Partners Foundation
Phase 3 Completed
NCT01487174 2022-05-13
KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With Progression After First- or Second-Line Chemotherapy
Kadmon Corporation, LLC
Phase 3 Terminated
NCT01244191 2021-04-06
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer
Daiichi Sankyo
Phase 3 Terminated
NCT02893332 2021-02-03
Sindas
Sichuan Provincial People's Hospital
Phase 3 Terminated
NCT00130728 2021-01-14
A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer
Genentech, Inc.
Phase 3 Completed
NCT00402779 2020-04-21
Erlotinib Prevention of Oral Cancer (EPOC)
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00026338 2020-04-02
Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer
Canadian Cancer Trials Group
Phase 3 Completed
NCT01667562 2019-12-20
ESSENCE
Hoffmann-La Roche
Phase 3 Completed
NCT03529084 2019-11-22
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Novartis
Phase 3 Withdrawn
NCT00153803 2019-09-06
Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)
Dartmouth-Hitchcock Medical Center
Phase 3 Completed
NCT02488330 2019-07-23
An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
Hoffmann-La Roche
Phase 3 Completed
NCT00901901 2019-05-30
SEARCH
Bayer
Phase 3 Completed
NCT00300586 2019-05-28
IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer
Hospices Civils de Lyon
Phase 3 Completed
NCT02775006 2019-04-30
Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma
The Netherlands Cancer Institute
Phase 3 Terminated
NCT02889692 2019-04-11
Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma
Shanghai University of Traditional Chinese Medicine
Phase 3 Completed
NCT01523587 2019-02-15
LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
Boehringer Ingelheim
Phase 3 Completed
NCT00096265 2018-03-09
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00364351 2018-01-25
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
Sanofi
Phase 3 Completed
NCT02134015 2018-01-23
HER3-Lung
Daiichi Sankyo
Phase 3 Terminated
NCT00036647 2018-01-10
OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
Astellas Pharma Inc
Phase 3 Completed
NCT00040183 2018-01-10
OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Astellas Pharma Inc
Phase 3 Completed
NCT01351415 2017-09-18
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 3 Completed
NCT02178397 2017-07-17
FLARE
Centre Francois Baclesse
Phase 3 Terminated
NCT01360554 2017-05-24
ARCHER 1009
Pfizer
Phase 3 Completed
NCT02694536 2017-03-24
A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT02031744 2017-03-14
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT01024413 2017-03-01
Phase III Trial to Evaluate the Elortinib vs Gefitinib in Advanced NSCLC With EGFR Exon 19 or 21 Mutations
Chinese Society of Lung Cancer
Phase 3 Completed
NCT02795884 2016-12-30
Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation
Yonsei University
Phase 3 Withdrawn
NCT01377376 2016-12-07
ATTENTION
Kyowa Kirin Co., Ltd.
Phase 3 Terminated
NCT00412217 2016-11-25
A Study of Erlotinib (Tarceva) in Participants With Resected Head and Neck Squamous Cell Cancer
Hoffmann-La Roche
Phase 3 Terminated
NCT01456325 2016-11-02
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Genentech, Inc.
Phase 3 Completed
NCT01887886 2016-11-02
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Hoffmann-La Roche
Phase 3 Completed
NCT01328951 2016-10-28
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
Hoffmann-La Roche
Phase 3 Completed
NCT01887795 2016-08-25
Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Phase 3 Completed
NCT00257608 2016-04-18
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
Genentech, Inc.
Phase 3 Completed
NCT00349219 2016-01-15
TORCH
National Cancer Institute, Naples
Phase 3 Completed
NCT00883779 2015-12-14
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00265824 2015-12-11
DREAM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Completed
NCT00634725 2015-12-11
Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Completed
NCT00738881 2015-10-29
MARVEL
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00373425 2015-09-17
RADIANT
Astellas Pharma Inc
Phase 3 Completed